Obseva (NASDAQ:OBSV) is set to announce its earnings results before the market opens on Monday, August 5th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter.
Obseva (NASDAQ:OBSV) last issued its earnings results on Thursday, May 9th. The company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.09). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. On average, analysts expect Obseva to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of OBSV opened at $8.96 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.73 and a current ratio of 6.73. The company has a 50-day moving average price of $10.50. The firm has a market cap of $408.84 million, a P/E ratio of -4.69 and a beta of 0.92. Obseva has a one year low of $8.83 and a one year high of $19.40.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Read More: What is quantitative easing?
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.